Lubrizol Life Science Health (LLS), a Berkshire Hathaway Company, has introduced its ASTAGILE microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina, it was reported on Wednesday.
Both ingredients have been combined in a patent-pending product aimed to promote mental agility and support healthy ageing for young and senior adults.
Astaxanthin is a carotenoid found in freshwater microalgae, while spirulina is a type of algae. In order to create the synergistic algae blend, LLS Health collaborated with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology. LLS claims that recent studies showed the cognitive enhancement effects of ASTAGILE, including a boost in memory performance, cognition and learning capabilities, and provided antioxidant and anti-inflammatory protection to the brain.
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress